Physician profile
Brian C Gross
NPI 1831327089
$9,466.00
in general payments reported to CMS, 2019-2025
22 companies · $970 in 2025
The $970 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $302 · 2021: $2,106 · 2022: $2,632 · 2023: $1,750 · 2024: $1,297 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $5,632.79 | 2021-2025 | Inspire |
| Medical Device Business Services, INC. | $905.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $601.54 | 2019-2024 | Dupixent |
| Genzyme Corporation | $493.96 | 2019-2024 | |
| Optinose US, INC. | $351.40 | 2019-2022 | |
| Stryker Corporation | $301.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $279.13 | 2021-2025 | Nucala |
| Intersect Ent, INC. | $210.93 | 2020-2022 | |
| Depuy Synthes Sales INC. | $204.54 | 2021 | |
| Kaleo, INC. | $93.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $79.24 | 2021-2025 | Keytruda |
| Itamar Medical INC | $64.82 | 2021-2023 | Watchpatone |
| Smith+Nephew, INC. | $49.31 | 2024 | Halo, Tula |
| Ambu INC. | $44.49 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.33 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.03 | 2024 | Ligasure |
| Arbor Pharmaceuticals, INC. | $21.93 | 2019 | |
| Kerecis Limited | $19.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Olympus America INC. | $18.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2025 | Tezspire |
| Phadia US INC. | $14.74 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.93 | 2025 | Nuzyra, Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.